IS2639B - Staðbundin lyfjablanda - Google Patents

Staðbundin lyfjablanda

Info

Publication number: IS2639B
Authority: IS; Iceland
Prior art keywords: topical formulations; administering; inhibitor; observed; dosage form
Prior art date: 2002-05-28

Application number

IS7612A

Other languages

English (en)

Other versions

IS7612A (is

Inventor

Christina Bolle

Rudolf Linder

Original Assignee

Nycomed Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-28

Filing date

2004-12-23

Publication date

2010-06-15

2004-12-23 Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh

2004-12-23 Publication of IS7612A publication Critical patent/IS7612A/is

2010-06-15 Publication of IS2639B publication Critical patent/IS2639B/is

Links

239000012049 topical pharmaceutical composition Substances 0.000 title 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dispersion Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Oncology (AREA)
Neurology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

IS7612A 2002-05-28 2004-12-23 Staðbundin lyfjablanda IS2639B (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP02011830		2002-05-28
DE10223828		2002-05-28
DE10311613		2003-03-14
PCT/EP2003/005524 WO2003099334A1 (en)	2002-05-28	2003-05-27	Topically applicable pharmaceutical preparation

Publications (2)

Publication Number	Publication Date
IS7612A IS7612A (is)	2004-12-23
IS2639B true IS2639B (is)	2010-06-15

Family

ID=29587313

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7612A IS2639B (is)	2002-05-28	2004-12-23	Staðbundin lyfjablanda

Country Status (32)

Country	Link
US (7)	US20060084684A1 (is)
EP (3)	EP1511516B1 (is)
JP (3)	JP5652983B2 (is)
KR (2)	KR20050014844A (is)
CN (3)	CN101491520B (is)
AT (2)	ATE417628T1 (is)
AU (2)	AU2003240719B2 (is)
BR (2)	BR0311339A (is)
CA (2)	CA2486917C (is)
CY (2)	CY1110312T1 (is)
DE (2)	DE60334692D1 (is)
DK (3)	DK2020243T3 (is)
EA (2)	EA020569B1 (is)
ES (3)	ES2354971T3 (is)
HR (1)	HRP20041211B1 (is)
HU (1)	HUE039709T2 (is)
IL (3)	IL164935A (is)
IS (1)	IS2639B (is)
LT (1)	LT2020243T (is)
MA (1)	MA27813A1 (is)
ME (1)	ME00565A (is)
MX (2)	MXPA04011612A (is)
NO (2)	NO334882B1 (is)
NZ (3)	NZ536920A (is)
PL (3)	PL212134B1 (is)
PT (3)	PT1511481E (is)
RS (1)	RS51104B (is)
SI (2)	SI2020243T1 (is)
TR (1)	TR201815573T4 (is)
UA (2)	UA81910C2 (is)
WO (2)	WO2003099278A1 (is)
ZA (2)	ZA200408649B (is)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872382B1 (en)	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) *	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
US20060084684A1 (en) *	2002-05-28	2006-04-20	Altana Pharma Ag	Topically applicable pharmaceutical preparation
JP2006502183A (ja)	2002-09-20	2006-01-19	アルコン，インコーポレイテッド	ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
FR2851247B1 (fr) *	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
SI1606261T1 (sl)	2003-03-10	2010-03-31	Nycomed Gmbh	Novi postopek za pripravo roflumilasta
CA2552524A1 (en) *	2004-01-10	2005-07-28	Biolipid, Inc.	Lipid compositions and methods of use
DE102004046235A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
DE102004046236A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
US8017633B2 (en)	2005-03-08	2011-09-13	Nycomed Gmbh	Roflumilast for the treatment of diabetes mellitus
US8663694B2 (en) *	2005-03-16	2014-03-04	Takeda Gmbh	Taste masked dosage form containing roflumilast
US20090209599A1 (en) *	2005-06-09	2009-08-20	Yoko Endo	Eye drop containing roflumilast
EP1992622B1 (en)	2006-02-21	2011-07-27	Eisai R&D Management Co., Ltd.	4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
CA2678477A1 (en)	2007-02-16	2008-08-21	Eisai R&D Management Co., Ltd.	Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
EP2202229B1 (en)	2007-08-17	2012-03-14	Eisai R&D Management Co., Ltd.	Novel preparation for external use
ATE538102T1 (de)	2007-08-17	2012-01-15	Eisai R&D Man Co Ltd	Verfahren zur herstellung eines chinazolinderivats
US20120270954A1 (en)	2009-10-30	2012-10-25	Yuanlong Pan	Methods for maintaining eye health and ameliorating opthalmic maladies in canines
ES2377785B2 (es)	2010-09-08	2012-09-26	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento del ojo seco.
ES2408132B1 (es) *	2010-09-08	2014-04-04	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento de la epífora.
JP2014511393A (ja) *	2011-03-07	2014-05-15	セルジーンコーポレイション	イソインドリン化合物を用いた疾患の治療方法
CN102793684B (zh) *	2011-05-26	2016-02-17	杭州赛利药物研究所有限公司	罗氟司特液体制剂及其制备方法
EA201400064A1 (ru) *	2011-06-28	2014-05-30	Байер Хелфкеэ Ллк	Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
CN104379180A (zh) *	2012-04-10	2015-02-25	佐治亚州立大学研究基金会公司	用cyld抑制剂治疗中耳炎及其它病状的组合物和方法
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
CN103570610B (zh) *	2012-07-18	2017-08-11	重庆华邦制药有限公司	一种罗氟司特微粒的制备方法
US9737521B2 (en) *	2012-11-08	2017-08-22	Rhizen Pharmaceuticals Sa	Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
ES2888074T3 (es)	2013-08-16	2021-12-30	Univ Maastricht	Tratamiento del deterioro cognitivo con inhibidor de PDE4
CN105434328A (zh) *	2014-09-01	2016-03-30	天津药物研究院有限公司	一种含罗氟司特固体分散体的固体制剂及其制备方法
US9969688B2 (en)	2014-10-24	2018-05-15	Hisamitsu Pharmaceutical Co., Inc.	Roflumilast prodrugs
CN104997959A (zh) *	2015-08-21	2015-10-28	蔡宇平	一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) *	2016-07-11	2019-10-01	赵晨	一种遗传性Usher综合征的致病突变及其检测试剂
US20200155524A1 (en) *	2018-11-16	2020-05-21	Arcutis, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en)	2017-06-07	2024-06-18	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en)	2018-11-16	2024-07-23	Arcutis Biotherapeutics, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en)	2017-06-07	2021-09-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en)	2017-06-07	2021-06-03	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en)	2017-06-07	2018-02-20	Arcutis, Inc.	Inhibition of crystal growth of roflumilast
US11534493B2 (en) *	2017-09-22	2022-12-27	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) *	2018-03-13	2018-07-17	兆科药业（广州）有限公司	一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
JP7492918B2 (ja) *	2018-06-04	2024-05-30	アーキュティス・バイオセラピューティクス・インコーポレーテッド	ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
KR102117525B1 (ko) *	2018-07-09	2020-06-01	건양대학교 산학협력단	Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
IL295172A (en) *	2020-01-31	2022-09-01	Arcutis Biotherapeutics Inc	Composition of topical roflumilest with improved administration and half-life in plasma
KR20220074935A (ko) *	2020-05-07	2022-06-03	아큐티스 바이오테라퓨틱스, 인크.	높은 크라프트 온도 음이온성 계면활성제를 이용한 피부병의 치료
EP4255393B1 (en)	2020-12-04	2025-05-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having antifungal properties
WO2022169615A1 (en)	2021-02-05	2022-08-11	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (zh) *	2021-02-10	2023-10-10	洛利克斯治疗有限公司	眼部递送罗氟司特的方法
JP2024506384A (ja) *	2021-02-10	2024-02-13	イオリクスセラピューティクス，インコーポレーテッド	ロフルミラストの眼科的送達方法
BR112023025185A2 (pt) *	2021-06-01	2024-02-27	Eyedea Bio Llc	Sistema de liberação de fármaco de liberação prolongada para fármacos oculares e métodos de uso
CA3231766A1 (en) *	2021-09-22	2023-03-30	Elizabeth W. JEFFORDS	Methods of treating ocular inflammatory diseases
CA3242833A1 (en)	2021-12-17	2023-06-22	Alcon Inc.	Ophthalmic pharmaceutical compositions and uses thereof
CA3242322A1 (en)	2021-12-28	2023-07-06	Arcutis Biotherapeutics, Inc.	Topical roflumilast aerosol foams
AU2023342481A1 (en)	2022-09-15	2025-04-10	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
WO2025054483A1 (en)	2023-09-07	2025-03-13	Arcutis Biotherapeutics, Inc.	Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) *	2023-09-15	2025-03-20	Arcutis Biotherapeutics, Inc.	Methods of reducing itch using topical roflumilast compositions
WO2025080415A1 (en)	2023-10-12	2025-04-17	Alto Neuroscience, Inc.	Treatment of neuropsychiatric disorders with tilivapram
CN117462487A (zh) *	2023-11-29	2024-01-30	沈阳药科大学	一种罗氟司特油凝胶及其制备方法
WO2025221488A1 (en)	2024-04-16	2025-10-23	Alto Neuroscience, Inc.	Transdermal administration of pde4 inhibitors for reduction in adverse events
WO2025265054A2 (en)	2024-06-21	2025-12-26	Arcutis Biotherapeutics, Inc.	Methods of treatment using topical roflumilast compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753945A (en) *	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) *	1988-05-31	1991-04-30	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) *	1992-09-14	1999-04-06	Wolf-Georg Forssmann	Use of inhibitors of phosphodiesterase IV
CN1046939C (zh) *	1993-07-02	1999-12-01	比克·古尔顿·劳姆贝尔格化学公司	氟烷氧基取代的苯甲酰胺类及其制备方法和应用
CN1128955A (zh) *	1993-08-10	1996-08-14	藤泽药品工业株式会社	经皮吸收制剂
ZA954599B (en) *	1994-06-07	1996-01-26	Allergan Inc	Stable gel formulation for topical treatment of skin conditions
AU5758199A (en) *	1998-09-29	2000-04-17	Fujisawa Pharmaceutical Co., Ltd.	Novel salts of pyridopyrazine compound and crystals thereof
US6395746B1 (en) *	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) *	1998-10-13	2002-01-17	John Kung	Composition to enhance permeation of topical skin agents
JP2002538207A (ja)	1999-03-10	2002-11-12	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	多発性硬化症治療のための３−シクロプロピルメトキシ−４−ジフルオロメトキシ−ｎ−（３，５−ジクロロピリド−４−イル）ベンズアミド
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
SK7292002A3 (en) *	1999-10-29	2002-12-03	Smithkline Beecham Corp	Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4
PL357555A1 (en) *	2000-01-31	2004-07-26	Pfizer Products Inc.	Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
JP2004502643A (ja) *	2000-02-16	2004-01-29	ユニバーシティ・オブ・ネブラスカ・メディカル・センター	線維症性疾患の治療法および治療用組成物
AU2001261962B2 (en) *	2000-05-25	2005-04-21	Merck Frosst Canada Ltd	Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
CA2427814C (en) *	2000-11-07	2009-06-02	Merck & Co., Inc.	A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) *	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) *	2001-11-09	2003-05-15	Johannes Barsig	Combination
US20060084684A1 (en) *	2002-05-28	2006-04-20	Altana Pharma Ag	Topically applicable pharmaceutical preparation

2003
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 EP EP03755048A patent/EP1511516B1/en not_active Expired - Lifetime
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Ceased
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
- 2003-05-27 EP EP03730122A patent/EP1511481B1/en not_active Expired - Lifetime
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/en not_active Expired - Lifetime
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en not_active Ceased
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active Expired - Fee Related
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en not_active Ceased
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20041211A2 (hr)	2006-04-30
EP1511516A1 (en)	2005-03-09
EP1511481B1 (en)	2010-10-27
IL165065A (en)	2010-11-30
JP2005529928A (ja)	2005-10-06
ATE485821T1 (de)	2010-11-15
IS7612A (is)	2004-12-23
DE60334692D1 (de)	2010-12-09
JP2005529930A (ja)	2005-10-06
EA020569B1 (ru)	2014-12-30
KR101307093B1 (ko)	2013-09-11
ATE417628T1 (de)	2009-01-15
NO20045656L (no)	2004-12-27
HK1079445A1 (zh)	2006-04-07
DK1511481T3 (da)	2011-01-24
ES2693094T3 (es)	2018-12-07
IL209657A0 (en)	2011-02-28
UA81910C2 (uk)	2008-02-25
ME00565A (en)	2011-12-20
SI1511516T1 (sl)	2009-06-30
CN101491520B (zh)	2011-03-16
US20140303215A1 (en)	2014-10-09
CA2486917C (en)	2011-11-22
EA200401517A1 (ru)	2005-06-30
PL372082A1 (en)	2005-07-11
IL164935A (en)	2010-12-30
CN1655823A (zh)	2005-08-17
PT2020243T (pt)	2018-11-09
NO334882B1 (no)	2014-06-30
HK1079437A1 (en)	2006-04-07
EA010416B1 (ru)	2008-08-29
CN101491520A (zh)	2009-07-29
WO2003099334A1 (en)	2003-12-04
US20060084685A1 (en)	2006-04-20
NO20045506L (no)	2004-12-16
ZA200409584B (en)	2006-05-31
DK2020243T3 (en)	2018-11-19
NO334916B1 (no)	2014-07-14
DE60325354D1 (de)	2009-01-29
RS51104B (sr)	2010-10-31
PL211870B1 (pl)	2012-07-31
HUE039709T2 (hu)	2019-01-28
KR20110122230A (ko)	2011-11-09
JP5683538B2 (ja)	2015-03-11
US20110313005A1 (en)	2011-12-22
MA27813A1 (fr)	2006-04-03
RS101404A (sr)	2007-02-05
EP1511481A1 (en)	2005-03-09
JP2012229245A (ja)	2012-11-22
BR0311339A (pt)	2005-03-22
EP2020243A1 (en)	2009-02-04
EP2020243B1 (en)	2018-08-15
NZ553731A (en)	2007-07-27
HRP20041211B1 (hr)	2013-06-30
AU2003240719B2 (en)	2009-12-10
EA200702588A1 (ru)	2008-08-29
PL212134B1 (pl)	2012-08-31
CY1121133T1 (el)	2019-12-11
IL164935A0 (en)	2005-12-18
PL372095A1 (en)	2005-07-11
UA88523C2 (ru)	2009-10-26
CN1655782A (zh)	2005-08-17
US20080280958A1 (en)	2008-11-13
CA2486910C (en)	2011-11-29
US20210116207A1 (en)	2021-04-22
PT1511481E (pt)	2011-01-14
MXPA04011612A (es)	2005-03-07
DK1511516T3 (da)	2009-04-06
CN100490804C (zh)	2009-05-27
WO2003099278A1 (en)	2003-12-04
CA2486917A1 (en)	2003-12-04
ES2319517T3 (es)	2009-05-08
TR201815573T4 (tr)	2018-11-21
US20060084684A1 (en)	2006-04-20
JP5652983B2 (ja)	2015-01-14
AU2003232828B2 (en)	2010-06-24
AU2003232828A1 (en)	2003-12-12
ES2354971T3 (es)	2011-03-21
LT2020243T (lt)	2018-11-12
CA2486910A1 (en)	2003-12-04
NZ537308A (en)	2009-09-25
BR0311337A (pt)	2005-03-15
IL165065A0 (en)	2005-12-18
US20190029956A1 (en)	2019-01-31
AU2003240719A1 (en)	2003-12-12
PT1511516E (pt)	2009-02-20
KR20050014844A (ko)	2005-02-07
EP1511516B1 (en)	2008-12-17
ZA200408649B (en)	2007-12-27
MXPA04011528A (es)	2005-02-14
SI2020243T1 (sl)	2018-11-30
NZ536920A (en)	2007-04-27
CN1655823B (zh)	2010-05-26
PL397021A1 (pl)	2012-03-26
CY1110312T1 (el)	2015-01-14

Publication	Publication Date	Title
IS2639B (is)	2010-06-15	Staðbundin lyfjablanda
UA84266C2 (uk)	2008-10-10	Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
AU1708202A (en)	2002-06-18	Organic compounds
AU2002211863A1 (en)	2002-04-15	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
SE0102440D0 (sv)	2001-07-05	New compound
ATE337016T1 (de)	2006-09-15	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen